head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue4
Subject Area: Medicine
DOI: 10.5272/jimab.2018244.2196
Published online: 15 October 2018

Original article

J of IMAB. 2018 Oct-Dec;24(4):2196-2200
Denitsa Tsaneva-Damyanova1ORCID logo Corresponding Autoremail, Elitsa Golkocheva-Markova2ORCID logo, Liliya Ivanova1,3, Tsvetelina Kostadinova4ORCID logo, Zhivka Stoykova1,3ORCID logo,
1) Department of Microbiology and Virology-Medical University, Varna, Bulgaria.
2) NRL Hepatitis viruses, National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria.
3) Laboratory of Clinical Virology-University hospital St. Marina, Varna, Bulgaria.
4) Section Medical Lab Technicians, Medical College, Medical University, Varna, Bulgaria.

Background: Occult hepatitis B infection (OBI) is a challenge in virology and a clinically relevant topic. The present study assessed the presence of HBV-DNA in serum samples of HBsAg negative, patients with data of liver dysfunction, positive for anti- HBc total Ab with or without anti-Hbs Ab.
Purpose: The goal of this study was to evaluate the prevalence of occult hepatitis B in Varna region, among patients with chronic liver dysfunction.
Materials and methods: The investigation was conducted among 79 people, predominantly patients at Gastroenterology Clinic in the University Hospital St. ”Marina”, Varna, Bulgaria. Quantitative determination of HBV DNA was performed in the National Reference Laboratory for Hepatitis viruses at the National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Results: From 79 investigated patients with liver dysfunction16 (20. 25%), were considered as occult HBV carriers. Fourteen of them (17.72%) were positive for HBV DNA with very low values,  below 200 IU/ml. Two of the cases (2.53%) were with serum levels comparable to those usually detected in the different phases of serologically evident (overt) infection and are considered as “false” OBI.
Conclusions: Our data showed that OBI is more widespread than expected and can be identified as a significant risk factor for the presence of more severe liver damages and an important oncogenic factor for developing cirrhosis and hepatocellular carcinoma.

Keywords: Hepatitis B, Occult hepatitis B infection (OBI), Anti-HBc total Ab, HBV DNA,

pdf - Download FULL TEXT /PDF 640 KB/
Please cite this article as: Tsaneva-Damyanova D, Golkocheva-Markova E, Ivanova L, Kostadinova T, Stoykova Z. Occult Hepatitis B Virus Infection Among Patients with Liver Dysfunction in Varna, Bulgaria. J of IMAB. 2018 Oct-Dec;24(4):2196-2200. DOI: 10.5272/jimab.2018244.2196

Corresponding AutorCorrespondence to: Denitsa Tsaneva-Damyanova; Department of Microbiology and Virology-Medical University, Varna; 3, Bregalnitsa Str., Varna, Bulgaria; E-mail: dr.tsaneva@gmail.com

1. Oscana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol. 2011 Mar 28;17(12):1553-7. [PubMed] [Crossref]
2. Said Z. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011 Apr 21;17(15):1927-38.  [PubMed] [Crossref]
3. Morales-Romero J, Vargas G, Garcia-Roman R. Occult HBV Infection: A faceless enemy in liver cancer development. Viruses. 2014  Apr 8;6(4):1590-611. [PubMed] [Crossref]
4. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008 Oct;49(4):652-7. [PubMed] [Crossref]
5. Thibault V, Pichould C, Mullen C, Rhoads J, Smith J, Bitbol A, et al. Characterization of a new sensitive PCR assay for quantification viral DNA isolated from patients with hepatitis B virus infection. J Clin Microbiol. 2007 Dec;45(12):3948-53. [PubMed] [Crossref]
6. Gonzales JM, Navarro JLL, de Santiago ER, Martinez AA. Diagnosis and management of occult hepatitis B virus infection: a short review. EMJ Hepatol. 2015; 3(1):63-69.
7. Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016 Oct 21;22(39):8720-8734. [PubMed] [Crossref]
8. Shih C, Chou SF, Yang CC, Huang JY, Choijilsuren G, Jhou RS. Control and eradication strategies of hepatitis B virus. Trends Microbiol. 2016 Sep;24(9):739-749. [PubMed] [Crossref]
9. Sharifi-Mood B, Sanei-Moghaddam E, Ghasem-Zadeh I, Khosravi S. Occult hepatitis B infection among Anti-HBc only positive individuals in the southeast of Iran in high prevalence of HBV infection region. IRSMJ. 2009; 11(1):90-92.
10. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006 May;36 Suppl 1:S33-44. [PubMed] [Crossref]
11. Martinez MC, Kok CC, Baleriola C, Robertson P, Rawlinson WD. Investigation of occult hepatitis B virus infection in anti-hbc positive patients from a liver clinic. PLoS One. 2015 Mar 12;10(3):e0117275. [PubMed] [Crossref]
12. Rusev V, Ivanova L. HBV and HCV markers among different age groups inVarna region population. BulgMed. 2003, 11(3): 20-22. [in Bulgarian]
13. Thomas E, Yoneda M, Schiff ER. Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med. 2015 Feb 2;5(2):a021345. [PubMed] [Crossref]
14. Minuk G, Sun D, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005 Apr;42(4):480-5. [PubMed] [Crossref]
15. Urbani S, Fagnoni F, Misale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010; 48(1):23-29. [PubMed] [Crossref]
16. Tsaneva-Damyanova D, Ivanova L. Seroepidemiological investigation of hepatitis B virus core antibody (anti-HBc total) carriers in Northeastern Bulgaria. Meditsinski Pregled / Medical Review. 2016; 52(5):40-45. [in Bulgarian]
17. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Raterini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘’occult’’. Hepatology. 2001 Jul;34(1):194-203. [PubMed] [Crossref]
18. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clinical Microbiol Rev. 2012 Jan;25(1):142-63. [PubMed] [Crossref]
19. Buti M, Fung S, Gane E, Afdhal N, Flisiak R, Gurel S, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxilfumarate for up to 5 years. HepatolInt. 2015 Apr;9(2):243-50. [PubMed] [Crossref]
20. Song le H, Xuan NT, Toan NL, Binh VQ, Boldt AB, Kremsner PG, et al. Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. Eur Cytokine Netw. 2008 Dec;19(4):204-10. [PubMed] [Crossref].

Received: 09 July 2018
Published online: 15 October 2018

back to Online Journal